论文部分内容阅读
目的观察孟鲁司特钠对支气管哮喘患者血清白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)水平及肺功能的影响。方法选取2012年4月~2014年1月在川北医学院附属医院接受治疗的68例急性发作期支气管哮喘患者,采用分层随机化方法将其分为对照组和治疗组,每组各34例。两组均常规给予吸氧、补液、吸入短效β2受体激动剂及激素等治疗措施,治疗组在此基础上口服孟鲁司特钠片10 mg/次,每晚1次,连用3个月。两组均于治疗前和治疗3个月后抽取静脉血检测TNF-α、IL-10水平和肺功能变化。结果与治疗前比较,两组治疗后TNF-α水平明显下降(P<0.01),治疗组较对照组下降更加明显(P<0.01);两组治疗后IL-10水平明显上升(P<0.01),治疗组较对照组上升更为明显(P<0.01);两组治疗后肺功能指标明显改善(P<0.01),治疗组较对照组改善更明显(P<0.01)。结论孟鲁司特钠可降低TNF-α水平,上调IL-10水平,从而抑制气道炎症,降低气道高反应性,改善肺功能。
Objective To observe the effect of montelukast on serum interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and lung function in patients with bronchial asthma. Methods Sixty-eight patients with acute exacerbation of bronchial asthma who were treated in Affiliated Hospital of North Sichuan Medical College from April 2012 to January 2014 were selected and divided into control group and treatment group by stratified randomization method, with 34 cases in each group . Both groups were routinely given oxygen therapy, rehydration, short-acting inhaled β2 agonists and hormones and other treatment measures, the treatment group on the basis of oral montelukast sodium tablets 10 mg / time, once a night, once every 3 month. Venous blood samples were collected before treatment and 3 months after treatment for TNF-α, IL-10 and lung function changes. Results Compared with those before treatment, the levels of TNF-α decreased significantly in both groups (P <0.01), and decreased more significantly in the treatment group than those in the control group (P <0.01). The levels of IL-10 in both groups significantly increased after treatment (P <0.01). The indexes of pulmonary function in the two groups were significantly improved after treatment (P <0.01), and the improvement in the treatment group was more obvious than that in the control group (P <0.01). Conclusion Montelukast sodium can reduce the level of TNF-α and up-regulate the level of IL-10, thereby inhibiting airway inflammation, reducing airway hyperresponsiveness and improving lung function.